Microenterprise Intervention to Reduce Sexual Risk Behaviors in Young Adults (EMERGE)
The Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) Project: Feasibility Trial of an Enhanced Microenterprise Intervention to Reduce Sexual Risk Behaviors in Young Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria are:
- African American;
- Aged 18-24;
- Living in Baltimore City;
- Having experienced one episode of homelessness in last 12 months;
- Unemployed or employed fewer than 10 hours per week;
- Not enrolled in school;
- Owning a mobile phone with text messaging function;
- Reporting at least one episode of unprotected/unsafe sex in prior 12 months
Exclusion criteria are:
- Aged 17 or younger;
- Older than 24 years;
- Unwilling to provide consent for study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
|
Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
|
|
Other: Control
Job announcements only
|
Participants will receive job announcements only.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants in Both Groups Who Have Responded to 70% or More of the Weekly Text Message Surveys
Time Frame: Measured at week 26
|
Proportion of participants in both groups who have responded to 70% or more of the weekly text message surveys (description)
|
Measured at week 26
|
|
Proportion of Intervention Participants Who Have Completed 70% or More of Intervention Activities (i.e., Text Message Receipt, Session Attendance, Grant Spending, and Mentor Contact)
Time Frame: Measured at week 23
|
Proportion of intervention participants who have completed 70% or more of intervention activities (i.e., text message receipt, session attendance, grant spending, and mentor contact) (description)
|
Measured at week 23
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of All Participants Who Receive One or More Informational Text Messages
Time Frame: Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
Proportion of all participants who receive one or more informational text messages (description)
|
Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
|
Proportion of All Participants Who Respond to the Text Message Survey
Time Frame: Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
Proportion of all participants who respond to the text message survey (description)
|
Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
|
Proportion of Intervention Participants Who Attend an Educational Session
Time Frame: Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
Proportion of intervention participants who attend an educational session (description)
|
Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
|
Proportion of Intervention Participants Who Receive One or More Mentor Contacts
Time Frame: Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
Proportion of intervention participants who receive one or more mentor contacts (description)
|
Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
|
Proportion of Intervention Participants Who Spend One or More Grant Payments
Time Frame: Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
Proportion of intervention participants who spend one or more grant payments (description)
|
Measured weekly at week 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
|
|
Proportion of Participants in Each Group Who Report One or More Unprotected Sex Acts in Last Week
Time Frame: Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
Proportion of participants in each group who report one or more unprotected sex acts in last week (description)
|
Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
|
Proportion of Participants in Each Group Who Report One or More Unprotected Sex Acts in Last Month
Time Frame: Measured at week 1 and 26
|
Proportion of participants in each group who report one or more unprotected sex acts in last month (description)
|
Measured at week 1 and 26
|
|
Proportion of Participants in Each Group Who Report One or More Safer Sex Acts in Last Week
Time Frame: Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
Proportion of participants in each group who report one or more safer sex acts in last week (description)
|
Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
|
Proportion of Participants in Each Group Who Report One or More Safer Sex Acts in Last Month
Time Frame: Measured at week 1 and 26
|
Proportion of participants in each group who report one or more safer sex acts in last month (description)
|
Measured at week 1 and 26
|
|
Proportion of Participants in Each Group Who Report One or More HIV Preventive Care-seeking or Information-seeking Acts in Last Week
Time Frame: Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
Proportion of participants in each group who report one or more HIV preventive care-seeking or information-seeking acts in last week (description)
|
Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
|
Proportion of Participants in Each Group Who Report One or More HIV Preventive Care-seeking or Information-seeking Acts in Last Month
Time Frame: Measured at week 1 and 26
|
Proportion of participants in each group who report one or more HIV preventive care-seeking or information-seeking acts in last month (description)
|
Measured at week 1 and 26
|
|
Proportion of Participants in Each Group Who Report One or More Paid Hours of Work in the Last Week
Time Frame: Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
Proportion of participants in each group who report one or more paid hours of work in the last week (description)
|
Measured weekly at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26
|
|
Proportion of Participants in Each Group Who Report One or More Paid Hours of Work in the Last Month
Time Frame: Measured weekly at week 1 and 26
|
Proportion of participants in each group who report one or more paid hours of work in the last month (description)
|
Measured weekly at week 1 and 26
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Larissa Jennings Mayo-Wilson, PhD MHS, Johns Hopkins Bloomberg School of Public Health
Publications and helpful links
General Publications
- Jennings Mayo-Wilson L, Coleman J, Timbo F, Latkin C, Torres Brown ER, Butler AI, Conserve DF, Glass NE. Acceptability of a feasibility randomized clinical trial of a microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices (EMERGE) in young adults: a mixed methods assessment. BMC Public Health. 2020 Dec 2;20(1):1846. doi: 10.1186/s12889-020-09904-x.
- Jennings Mayo-Wilson L, Coleman J, Timbo F, Ssewamala FM, Linnemayr S, Yi GT, Kang BA, Johnson MW, Yenokyan G, Dodge B, Glass NE. Microenterprise Intervention to Reduce Sexual Risk Behaviors and Increase Employment and HIV Preventive Practices Among Economically-Vulnerable African-American Young Adults (EMERGE): A Feasibility Randomized Clinical Trial. AIDS Behav. 2020 Dec;24(12):3545-3561. doi: 10.1007/s10461-020-02931-0.
- Mayo-Wilson LJ, Glass NE, Ssewamala FM, Linnemayr S, Coleman J, Timbo F, Johnson MW, Davoust M, Labrique A, Yenokyan G, Dodge B, Latkin C. Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices in economically-vulnerable African-American young adults (EMERGE): protocol for a feasibility randomized clinical trial. Trials. 2019 Jul 17;20(1):439. doi: 10.1186/s13063-019-3529-7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB00008833
- K01MH107310 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.